Abstract
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
| Original language | English |
|---|---|
| Journal | Reproductive BioMedicine Online |
| Volume | 38 |
| Issue number | 2 |
| Pages (from-to) | 249-259 |
| Number of pages | 11 |
| ISSN | 1472-6483 |
| DOIs | |
| Publication status | Published - 02.2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Centers: Center for Pre-Implantation Diagnostics (PID)
Fingerprint
Dive into the research topics of 'Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver